Search Results

INIMMUNE ANNOUNCES SUCCESSFUL PHASE 1 CLINICAL RESULTS FOR DISEASE MODIFYING ALLERGY TREATMENT, INI-2004

Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today the top line results from its Phase 1b Multiple Ascending Dose (MAD) study of INI-2004 in people suffering with Allergic Rhinitis (NCT06038279).

May 15, 2024

·

3 min read

Press Releases

Inimmune publishes positive proof of mechanism for TLR4 Agonist INI-2004 in Allergic Rhinitis

July 30, 2024

·

2 min read

Business

Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy

Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical-stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration.

January 8, 2024

·

4 min read

News

SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems

July 16, 2024

·

2 min read

BioForest

Inimmune Collaborates with Boston Children’S Hospital to Develop Novel Adjuvants

Inimmune Corporation announced that it has entered a research collaboration with Boston Children’s Hospital to develop novel and innovative small molecule vaccine adjuvants.

October 24, 2023

·

3 min read

Press Releases

INIMMUNE ANNOUNCES FIRST CANCER PATIENT DOSED IN PHASE 1 CLINICAL STUDY USING THE IMMUNOTHERAPEUTIC INI-4001, A NOVEL TLR7/8 AGONIST

July 24, 2024

·

2 min read

INIMMUNE TO PRESENT ON NOVEL ADJUVANTS AT THE 17TH VACCINE CONGRESS ON SEPTEMBER 26TH, 2023

Inimmune announced today that its Chief Operating Officer, Dr. David Burkhart, will give a plenary presentation at the upcoming 17th Vaccine Congress in Glasgow, Scotland September 24-27th.

September 21, 2023

·

3 min read

Drug Development

Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004

Inimmune Corporation (“Inimmune”) today announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development as a potential treatment of allergic rhinitis.

August 2, 2023

·

3 min read

Inimmune CSO Jay Evans to present an update on clinical stage programs at the International Precision Vaccine Conference in Rome, Italy on October 5-6

Inimmune announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will be a speaker at the International Precision Vaccines Conference (https://precisionvaccines2023.com/) in Rome, Italy on October 5-6.

September 28, 2023

·

2 min read

Inimmune to Play a Key Role at the World Vaccine Congress on April 3-6, 2023

Inimmune announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., and its Chief Operating Officer, David Burkhart, Ph.D., will play key roles at the World Vaccine Congress event.

March 29, 2023

·

2 min read